Arizona Biosciences News

MDS Pharma Services opens new Tempe clinical-trials facility

By Matt Ellsworth, Flinn Foundation

Summary:

MDS Pharma Services, which provides a variety of contract research and testing services for pharmaceutical and biotechnology firms, has opened a new Phase I clinical-trials facility in Tempe, more than doubling the company's capacity in the Phoenix area and significantly adding to the Valley's clinical research infrastructure.

Full Story:

By Matt Ellsworth, Flinn Foundation

MDS Pharma Facility Opening Group ShotMDS Pharma Services, which provides a variety of contract research and testing services for pharmaceutical and biotechnology firms, has opened a new Phase I clinical-trials facility in Tempe, more than doubling the company's capacity in the Phoenix area and significantly adding to the Valley's clinical research infrastructure.

MDS Pharma described the $25 million, 300-bed facility west of Interstate 10 on Baseline Road as the largest Phase I clinic on the West Coast. Currently, the firm employs approximately 150 staff in the Phoenix area, and could add another 300 employees by the time the Tempe clinic reaches capacity.

"The Phoenix location offers several advantages to our clients, including travel convenience, access to a large and varied study participant pool, and an experienced and educated workforce to staff the new clinic and laboratory," said David Spaight, president of MDS Pharma.

At the new facility's grand opening on Jan. 25, Bernadette Melnyk, dean of Arizona State University's College of Nursing and Healthcare Innovation, spoke about the significance of clinical research and the potential for partnership with MDS Pharma.

Linda Mottle, director of the College of Nursing's Center for Healthcare Innovation and Clinical Trials, said that she is working to develop strategic initiatives that will interface with the local clinical research community to take on shared foundational challenges. "MDS Pharma is a prominent clinical research CRO (contract research organization) and drug-development company," Mottle said. "We believe they will be a key leader in this arena."

Mottle added that ASU's recently initiated graduate certificate program in clinical research management requires a capstone project where students work with an organization in the community. "Our students will have the opportunity to work with MDS Pharma as one of our community partners," she said.

MDS Pharma, based in King of Prussia, Penn., is a unit of a Canadian life-sciences company, MDS Inc., which has 6,200 employees and operations in 28 countries. MDS Inc.'s market capitalization exceeds $2 billion.


For more information:

MDS Pharma Services media release